Antithrombotic therapy in peripheral artery disease

T. Raymond Foley, Stephen W. Waldo, Ehrin J. Armstrong

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Antiplatelet agents are recommended for the reduction of major adverse cardiovascular events among all patients with symptomatic peripheral artery disease. However, the optimal antiplatelet regimen and duration of therapy in peripheral artery disease (PAD) remains unclear, largely due to limited and conflicting data in this patient population. This article reviews current data on antithrombotic therapy in PAD and discusses the implications of this data for current practice and future research.

Original languageEnglish (US)
Pages (from-to)156-169
Number of pages14
JournalVascular Medicine (United Kingdom)
Issue number2
StatePublished - Apr 1 2016
Externally publishedYes


  • anticoagulants
  • arterial occlusive diseases
  • critical limb ischemia
  • intermittent claudication
  • peripheral artery disease
  • platelet aggregation inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Antithrombotic therapy in peripheral artery disease'. Together they form a unique fingerprint.

Cite this